MedTrace Logo

The Effect of Allopurinol on Insulin Resistance and Blood Pressure

NCT00639756 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-10-13

No results posted yet for this study

Summary

Studies in animals have found that allopurinol can markedly improve fructose induced metabolic syndrome. In this study we test the hypothesis that allopurinol may lower BP, reduce triglycerides, and improve metabolic parameters in subjects placed on a high fructose diet.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Allopurinol

Allopurinol 300 mg

DRUG

Placebo

Placebo given for 2 weeks

Sponsors & Collaborators

  • Hospital Mateo Orfila

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-08-31
Completion
2008-10-31

Countries

  • Spain

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00639756 on ClinicalTrials.gov